Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Research question finder
Find source-linked psilocybin evidence for a research question, explore matching publications and trial records, and keep findings separate from registration.
Free access · No subscription for research tools or data exports
Start with a question, then inspect the evidence
This finder connects questions to curated evidence and matching bibliographic records. It does not generate clinical advice or claim that a keyword match answers the question.
Selected evidence relevant to this question
These are original educational annotations from the evidence guide, not a new systematic review. Follow each original report and inspect its population, comparator, endpoint and safety findings.
Mertens et al. · EPISODE · 2026
Primary endpoint not metPrimary comparison not significant: response 17.0% with 25 mg versus 10.6% with nicotinamide; adjusted odds ratio 1.73 (95% CI 0.53–6.23), p=0.19.
The first hierarchical test failed; secondary symptom changes are exploratory. Two serious adverse reactions followed 25 mg, including one case of hallucinogen persisting perception disorder.
Source checked 2026-10-07Rucker et al. · NHS feasibility trial · 2026
Feasibility studyWeek-3 adjusted MADRS difference −10.41 points (95% CI −14.86 to −5.95), favoring psilocybin; the report describes persistence at week 6.
An encouraging symptom estimate from a feasibility study is not a confirmatory efficacy endpoint. A single site and six-week follow-up limit generalization.
Source checked 2026-10-07Yngwe et al. · Stockholm trial · 2026
Primary endpoint metDay-8 difference −7.27 points (95% CI −12.89 to −1.65), p=0.01. The clinician-rated difference was not significant at day 365: −3.68 (95% CI −9.30 to 1.94), p=0.20.
A small sample; later self-reported outcomes are secondary and differ from the clinician-rated endpoint. Two psilocybin participants reported persistent severe anxiety requiring medical attention.
Source checked 2026-10-07Raison et al. · 2023
Primary endpoint metBetween-group difference −12.3 points (95% CI −17.5 to −7.2), p<0.001, favoring psilocybin.
Six-week follow-up and selected eligibility. Participants using psychotropic medication could enter following taper. No serious treatment-emergent adverse events were reported, but overall and severe adverse events were more frequent with psilocybin.
Source checked 2026-10-07von Rotz et al. · 2023
Primary outcomes favored psilocybinGreater symptom reduction with psilocybin; reported MADRS between-group effect size d=0.97, p=0.0011.
The primary assessment was only two weeks after treatment. The selected sample and single-center design do not establish long-term effectiveness in routine care.
Source checked 2026-10-07Goodwin et al. · COMP001 · 2022
25 mg primary comparison significant25 mg versus 1 mg: −6.6 MADRS points (95% CI −10.2 to −2.9), p<0.001. The 10 mg comparison was not significant.
Sustained response at week 12 did not support the short-term result. Adverse events occurred in 77%; suicidal ideation, behavior or self-injury occurred across dose groups. This does not establish their cause.
Source checked 2026-10-07Carhart-Harris et al. · 2021
Primary endpoint not metPrimary between-group difference −2.0 points (95% CI −5.0 to 0.9), p=0.17; no statistically significant difference.
Several secondary outcomes favored psilocybin without correction for multiple comparisons. The primary result establishes neither superiority nor equivalence to escitalopram.
Source checked 2026-10-07Davis et al. · 2021
Positive waiting-list comparisonDepression ratings were lower in the immediate-treatment group than in the waiting-list group at the corresponding assessments.
A small evaluable sample and a waiting-list comparator. The design does not separate drug effects from expectancy, therapist contact and the treatment setting.
Source checked 2026-10-07Matching indexed literature
1676 records match depression. First 20 shown; status and source labels describe records, not an independent review of their findings.
Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression2026-11-01 · Crossref · PublishedPreparing the body for psilocybin therapy: receptive and generative interoception in cancer patients2026-10-08 · Crossref · PublishedNeuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's Disease2026-10-08 · ClinicalTrials.gov · CLINICAL TRIALPsilocybin use, mental health treatment utilization, and unmet treatment need among US individuals with depression.2026-10-06 · PubMed · PublishedPsilocybin-Assisted Therapy in Depressive Disorders: Clinical Governance, Safety, and Translational Challenges2026-10-05 · OpenAlex · PublishedCaution before canonisation: a clinical and implementation science perspective on psychedelics2026-10-05 · OpenAlex · PublishedAn Open-Label Multidose Psilocybin Intervention for Obsessive-Compulsive Disorder.2026-10-05 · medRxiv · PREPRINT (not peer reviewed)Study participant perceptions of the relevance of therapist and study team personal psychedelic experience2026-10-03 · OpenAlex · PublishedSerotonergic Toxicity and Hyponatremia Associated with Antidepressant Therapy: The Pivotal Role of SIADH.2026-10-03 · Europe PMC · PublishedPsilocybin2026-10-03 · Crossref · PublishedThe New Mexico Medical Psilocybin Act and current trends in the United States psychedelic policy2026-10-01 · Crossref · PublishedF25. COMPARING PSILOCYBIN-ASSISTED THERAPY AND SSRIS IN THE TREATMENT OF LATE-LIFE DEPRESSION2026-10-01 · Crossref · PublishedThe Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSD2026-10-01 · ClinicalTrials.gov · CLINICAL TRIALChronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats2026-10-01 · Crossref · PublishedWorsening of Depression and Anxiety With Psilocybin: A Case Report in Cyclothymia.2026-09-30 · Europe PMC · PublishedPsilocybin and ayahuasca in treatment-resistant depression: clinical evidence, methodological constraints and ethical challenges: a narrative review2026-09-30 · Europe PMC · PublishedPsilocybin in psychiatry: Current clinical evidence, mechanisms of action and translational perspectives. A literature review based on PubMed-indexed studies2026-09-29 · Crossref · PublishedTargeting the serotonin 1B receptor for the treatment of depression and anxiety.2026-09-28 · Europe PMC · PublishedThe Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease2026-09-28 · ClinicalTrials.gov · CLINICAL TRIALPsilocybin for Treatment-Resistant Major Depression: Efficacy, Safety and Therapeutic Mechanisms2026-09-24 · OpenAlex · Published
Search, refine and export these records